CoChat

Sympathetic Overactivity in Chronic Kidney Disease: Consequences and Mechanisms

Open access
Kaur, Jasdeep, Young, Benjamin, Fadel, Paul · 2017 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 156 of the 156 references it cites were found in a registry or an index.

Abstract

The incidence of chronic kidney disease (CKD) is increasing worldwide, with more than 26 million people suffering from CKD in the United States alone. More patients with CKD die of cardiovascular complications than progress to dialysis. Over 80% of CKD patients have hypertension, which is associated with increased risk of cardiovascular morbidity and mortality. Another common, perhaps underappreciated, feature of CKD is an overactive sympathetic nervous system. This elevation in sympathetic nerve activity (SNA) not only contributes to hypertension but also plays a detrimental role in the progression of CKD independent of any increase in blood pressure. Indeed, high SNA is associated with poor prognosis and increased cardiovascular morbidity and mortality independent of its effect on blood pressure. This brief review will discuss some of the consequences of sympathetic overactivity and highlight some of the potential pathways contributing to chronically elevated SNA in CKD. Mechanisms leading to chronic sympathoexcitation in CKD are complex, multifactorial and to date, not completely understood. Identification of the mechanisms and/or signals leading to sympathetic overactivity in CKD are crucial for development of effective therapeutic targets to reduce the increased cardiovascular risk in this patient group.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms18081682

Cites

156 of 156 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Original record of muscle sympathetic nerve activity (MSNA) in a normal subject and a renal failure patient on hemodialysis, demonstrating significantly greater resting MSNA in the dialysis patient. The bottom two panels display a portion of the neurogram and simultaneous electrocardiogram from the patient on hemodialysis showing that the renal failure patient has a burst of MSNA with every cardiac cycle. (Modified from Converse et al. [11] with permission).
Figure 1 Original record of muscle sympathetic nerve activity (MSNA) in a normal subject and a renal failure patient on hemodialysis, demonstrating significantly greater resting MSNA in the dialysis patient. The bottom two panels display a portion of the neurogram and simultaneous electrocardiogram from the patient on hemodialysis showing that the renal failure patient has a burst of MSNA with every cardiac cycle. (Modified from Converse et al. [11] with permission).CC BY · PubMed Central
Figure 2 Muscle sympathetic nerve activity (MSNA) expressed as burst frequency (bursts (bs)/min, A) and burst incidence (bs/100 heartbeats (hb), B) in subjects grouped according to their estimated glomerular filtration rate (eGFR), with the highest quartile of eGFR in group I and lowest quartile of eGFR in group IV. With decreasing eGFR, there is a significant and progressive increase in resting MSNA in chronic kidney disease (CKD) patients. * p < 0.05 significant difference between quartiles. (From Grassi et al. [13] with permission).
Figure 2 Muscle sympathetic nerve activity (MSNA) expressed as burst frequency (bursts (bs)/min, A) and burst incidence (bs/100 heartbeats (hb), B) in subjects grouped according to their estimated glomerular filtration rate (eGFR), with the highest quartile of eGFR in group I and lowest quartile of eGFR in group IV. With decreasing eGFR, there is a significant and progressive increase in resting MSNA in chronic kidney disease (CKD) patients. * p < 0.05 significant difference between quartiles. (From Grassi et al. [13] with permission).CC BY · PubMed Central
Figure 3 Mean arterial pressure (MAP) responses during 8-h continuous systemic infusion of the nitric oxide synthase (NOS) inhibitor l-nitroarginine methyl ester (l-NAME) in rats with sympathectomy (open circles) and without sympathectomy (closed circles). Although no difference was observed in the initial increase in MAP (removal of endothelium-mediated dilation), sympathectomy attenuated the sustained hypertensive response to l-NAME, demonstrating a sympathetic contribution to the blood pressure raising effects of systemic NOS inhibition. * p < 0.05 vs. control. (From Sander et al. [75] with permission).
Figure 3 Mean arterial pressure (MAP) responses during 8-h continuous systemic infusion of the nitric oxide synthase (NOS) inhibitor l-nitroarginine methyl ester (l-NAME) in rats with sympathectomy (open circles) and without sympathectomy (closed circles). Although no difference was observed in the initial increase in MAP (removal of endothelium-mediated dilation), sympathectomy attenuated the sustained hypertensive response to l-NAME, demonstrating a sympathetic contribution to the blood pressure raising effects of systemic NOS inhibition. * p < 0.05 vs. control. (From Sander et al. [75] with permission).CC BY · PubMed Central
Figure 4 Average mean arterial pressure, heart rate, and renal sympathetic nerve activity during continuous systemic infusion of asymmetric dimethylarginine (ADMA; an endogenous NOS inhibitor) in baroreceptor-intact (A) and baroreceptor-denervated animals (B). In comparison with barointact animals, barodenervated animals show a significant increase in renal SNA indicating frank sympathoexcitation in response to systemic ADMA infusion. * p < 0.05 vs. baseline; † p < 0.05 vs. baroreceptor intact. (From Augutyniak et al. [87] with permission.)
Figure 4 Average mean arterial pressure, heart rate, and renal sympathetic nerve activity during continuous systemic infusion of asymmetric dimethylarginine (ADMA; an endogenous NOS inhibitor) in baroreceptor-intact (A) and baroreceptor-denervated animals (B). In comparison with barointact animals, barodenervated animals show a significant increase in renal SNA indicating frank sympathoexcitation in response to systemic ADMA infusion. * p < 0.05 vs. baseline; † p < 0.05 vs. baroreceptor intact. (From Augutyniak et al. [87] with permission.)CC BY · PubMed Central
Figure 5 Schematic illustration depicting the effects of elevated ADMA in the brainstem and the peripheral circulation. Reduced dimethylarginine dimethylaminohydrolase (DDAH) activity and renal clearance of ADMA leads to elevated plasma ADMA concentrations in chronic kidney disesase (CKD). Elevated ADMA in the brainstem inhibits NOS and reduces central nitric oxide (NO) production, contributing to higher central sympathetic outflow. This greater SNA results in peripheral vasoconstriction. When prolonged, the sympathetic overactivity leads to a host of other deleterious consequences as outlined in the text of the review. In the periphery, elevated ADMA inhibits NOS and decreases NO, thereby reducing endothelium-mediated vasodilation. Greater sympathetically-mediated vasoconstriction and lower endothelium-mediated vasodilation contributes to increased vascular tone and higher blood pressure. ROS, reactive oxygen species; eNOS, endothelial nitric oxide synthase; NE, norepinephrine. ⱶ- denotes inhibition. (See text for further details).
Figure 5 Schematic illustration depicting the effects of elevated ADMA in the brainstem and the peripheral circulation. Reduced dimethylarginine dimethylaminohydrolase (DDAH) activity and renal clearance of ADMA leads to elevated plasma ADMA concentrations in chronic kidney disesase (CKD). Elevated ADMA in the brainstem inhibits NOS and reduces central nitric oxide (NO) production, contributing to higher central sympathetic outflow. This greater SNA results in peripheral vasoconstriction. When prolonged, the sympathetic overactivity leads to a host of other deleterious consequences as outlined in the text of the review. In the periphery, elevated ADMA inhibits NOS and decreases NO, thereby reducing endothelium-mediated vasodilation. Greater sympathetically-mediated vasoconstriction and lower endothelium-mediated vasodilation contributes to increased vascular tone and higher blood pressure. ROS, reactive oxygen species; eNOS, endothelial nitric oxide synthase; NE, norepinephrine. ⱶ- denotes inhibition. (See text for further details).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 168

Metadata

Authors
Kaur, J., Young, B., & Fadel, P.
Affiliations
The University of Texas at Arlington (US)
Corresponding author
Fadel, Paul
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2017-08-02
Volume
18
Issue
8
Pages
1682
ISSN
1422-0067 (ISSN-L)
OpenAlex
W2741868536
Cited by
168
References
156
Citations by year
2026: 19 · 2025: 27 · 2024: 25 · 2023: 14 · 2022: 17 · 2021: 23 · 2020: 16 · 2019: 16 · 2018: 9 · 2017: 1
FWCI
1.62
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Institutes of Health (NIH R01 HL127071)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
Keywords
chronic kidney disease, sympathetic nervous system, sympathoexcitation, sympathetic activity, hypertension, cardiovascular risk, chronic kidney disease progression, cardiovascular mortality, therapeutic target
MeSH terms
Animals, Humans, Hypertension, Renal, Sympathetic Nervous System, Renal Insufficiency, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.